{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:23Z","timestamp":1793120063007,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jhepr.2023.100975","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:53:23Z","timestamp":1701370403000},"page":"100975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-8392","authenticated-orcid":false,"given":"Harry L.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Sowah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-2414","authenticated-orcid":false,"given":"Cheng-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh-Hoa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-3813","authenticated-orcid":false,"given":"Jeffrey J.","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-6179","authenticated-orcid":false,"given":"Simon P.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Circe","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-6982","authenticated-orcid":false,"given":"Anna E.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Rod","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100975_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib2","series-title":"Hepatitis B","year":"2020"},{"key":"10.1016\/j.jhepr.2023.100975_bib3","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact","year":"2021"},{"key":"10.1016\/j.jhepr.2023.100975_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100975_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.09.011","article-title":"Hepatitis B virus reverse transcriptase - target of current antiviral therapy and future drug development","volume":"123","author":"Clark","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2023.100975_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262516","article-title":"Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy","volume":"17","author":"Burdette","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2023.100975_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2019.1678584","article-title":"Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B","volume":"15","author":"Yeh","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jhepr.2023.100975_bib8","first-page":"1070","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100975_bib9","doi-asserted-by":"crossref","first-page":"a021428","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhepr.2023.100975_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100975_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhepr.2023.100975_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2023.100975_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cells10051114","article-title":"CD4(+) T cells in chronic hepatitis B and T cell-directed immunotherapy","volume":"10","author":"Buschow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2023.100975_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhepr.2023.100975_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.582292","article-title":"The multiple functions of B cells in chronic HBV infection","volume":"11","author":"Cai","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2023.100975_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors - redefining innate immunity","volume":"13","author":"O'Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2023.100975_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1600-0854.2009.00899.x","article-title":"How location governs toll-like receptor signaling","volume":"10","author":"Chaturvedi","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.jhepr.2023.100975_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/cmi.2012.38","article-title":"TLR8: the forgotten relative revindicated","volume":"9","author":"Cervantes","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhepr.2023.100975_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhepr.2023.100975_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-11-1625","article-title":"VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC","volume":"18","author":"Lu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2023.100975_bib21","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1016\/j.vaccine.2010.06.117","article-title":"TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity","volume":"28","author":"Du","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jhepr.2023.100975_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib23","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100975_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100975_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.31255","article-title":"Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B","volume":"73","author":"Daffis","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100975_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP3363","article-title":"Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral toll-like receptor 8 agonist: a phase Ia study in healthy subjects","volume":"25","author":"Reyes","year":"2020","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2023.100975_bib29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/hep.31795","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100975_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00430-014-0369-7","article-title":"Natural history of chronic hepatitis B virus infection","volume":"204","author":"Busch","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhepr.2023.100975_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2023.100975_bib33","article-title":"One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: an observational study","volume":"101","author":"Chen","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2023.100975_bib34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100975_bib35","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhepr.2023.100975_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100975_bib37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100975_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2023.100975_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"J Viral Hepat"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923003063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:33:42Z","timestamp":1762900422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923003063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2589555923003063"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100975","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100975"}}